Corvus Pharmaceuticals, Inc. (CRVS) Earnings Call Transcript & Summary

August 8, 2022

NASDAQ US Health Care Biotechnology earnings 32 min

Earnings Call Speaker Segments

Executive

executive
#1

Thanks, operator, and welcome, everyone, on this afternoon's call. We appreciate your participation in Corvus Pharmaceuticals' conference call covering our Second Quarter 2022 Update and Financial Results. Joining us today to go over the results and business updates are Richard Miller, our Chief Executive Officer; Leiv Lea, our Chief Financial Officer; and James Rosenbaum, Senior Vice President of Research. The executive team will kick things off with prepared remarks, after which we'll move into a question-and-answer session. I want to remind everybody that remarks made by management today, along with responses to questions, will contain forward-looking statements. Such statements rest on estimates and assumptions as of today and carry risks and uncertainties that could lead actual results to differ materially from what those statements express or imply, including the risks and uncertainties laid out in Corvus' quarterly report on Form 10-Q, filed with the SEC today, as well as other filings the company periodically makes with the SEC. Unless the law requires otherwise, the company assumes no obligation to publicly update or revise any forward-looking statements. With that said, I'll hand the call over to Leiv Lea. Leiv?

Leiv Lea

executive
#2

Thanks, Aaron. First, I'll give a brief summary of how we performed financially in the second quarter of 2022, and after that I'll hand things to Richard for an update on the business. As of June 30, 2022, Corvus held cash, cash equivalents and marketable securities adding up to $56.7 million, versus $69.5 million on December 31, 2021. The key point, which Richard will cover, is that we've amortized our clinical-stage pipeline plans and pushed our cash runway out to early 2024. R&D expenses came to $4.9 million in Q2 2022, against $9.1 million during the equivalent period in 2021. As is evident, we keep managing our cash burn rate prudently while moving our portfolio of product candidates forward; we pull this off through careful use of seasoned staff, tapping outside resources, and setting up collaborations that assist in supporting development of what we're building. Take these collaborations as examples: Angel Pharmaceuticals, our China-based partner, is now taking part in clinical trials involving our ITK inhibitor; and the Kidney Cancer Consortium will run our frontline RCC trial using ciforadenant. Net loss for Q2 2022 reached $8.4 million, versus a net loss of $11.8 million during the same period in 2021. Total stock compensation expense for the second quarter of 2022 amounted to $0.7 million, versus $1.2 million during the equivalent period in 2021. Now I'll pass the call to Richard, who will go deeper into our strategy and plans.

Richard Miller

executive
#3

Thanks, Leiv, and good afternoon to all of you. We appreciate your joining us today as we share our business update for the second quarter of 2022; during the first six months of 2022, we achieved substantial momentum across our 3 clinical-stage programs, each of which is positioned well to enter mid-stage studies. Their capacity to deliver novel therapeutic approaches for a variety of diseases through modulation of activity along the tumor-immunity axis has us enthusiastic. While we keep moving our pipeline forward, we stay conscious of the biotech industry's present circumstances and are adjusting as needed. Prioritizing our portfolio happens continuously as part of how we develop programs; to lengthen the amount of time our cash can fund operations, our attention is directed toward those programs offering the greatest chance of creating value through meaningful clinical data in the near term. Drawing on recent clinical data along with preclinical research, we have reached a strategic choice to direct more resources toward our CPI-818 ITK inhibitor program. Our view is that this drug could present varied opportunities spanning oncology, autoimmunity and allergic diseases. Additionally, we intend to move ciforadenant forward into a Phase II frontline renal cell cancer trial alongside the Kidney Cancer Consortium. For mupadolimab, we will hold off on starting the randomized, blinded Phase II trial in lung cancer that had been previously planned, because of the time line to data as well as the CD73 landscape becoming increasingly crowded. Let me be clear: our belief in mupadolimab's great potential remains, and we look forward to moving its development ahead in the future; we still hold the view that mupadolimab stands apart from competitors because of its activation of B cells and its immunomodulatory properties. Now I will give an update on each program, beginning with CPI-818, our ITK inhibitor. During May, we held an R&D symposium in New York that gave a comprehensive background on the clinical and preclinical data that has us so enthusiastic about 818's potential for treating T-cell lymphomas as well as a range of indications spanning autoimmunity and allergy. A replay and slides from this event can be found on our website for anyone who has not yet had a chance to watch it. Below are several of the key points and updates from the symposium. CPI-818 is a covalent ITK inhibitor, and it binds to ITK in a manner comparable to how ibrutinib binds to BTK. It is widely recognized that ITK participates in T cell receptor signaling, homologous to BTK's participation in B cell receptor signaling. What is less well appreciated but clearly demonstrated by others in preclinical animal models is that ITK holds a crucial role in T cell differentiation. In our ongoing Phase I clinical trial in T-cell lymphoma, we have demonstrated that ITK also has a vital role in differentiation of normal human T cells. The Corvus team anticipated these findings, and in fact they were among our motivating factors for pursuing this drug. What we've discovered is that we can influence T cell differentiation, and when given at larger doses, we can also interrupt T cell receptor signaling. Together, this gives us a chance to create a highly significant new therapy. Beginning with lymphomas allowed us to assess a wide range of immunologic characteristics. The trial we conducted in T-cell lymphoma supplies the data and backs the reasoning for moving into additional immune conditions. This approach looks a lot like how other immunologically active drugs, including RITUXAN and ibrutinib, were developed — they too began in lymphoma before being extended to other diseases. As many of you are aware, anti-CD20 antibodies such as RITUXAN and BTK inhibitors are today commonly prescribed for B-cell lymphomas, and people on the Corvus team were instrumental in finding and developing these treatments. RITUXAN holds approval for multiple autoimmune conditions, and BTK inhibitors are being studied at different stages for those conditions too. Results from our worldwide Phase I/Ib study in T-cell lymphomas allowed us to pinpoint 200 milligrams taken orally twice daily as the best dose of CPI-818 for modulating T cell differentiation, and we're adding more patients to that dose group in the trial. The study continues alongside our collaborator in China, Angel Pharmaceuticals. We've sent in an abstract to share an update on these data at the ASH conference in December, should it be accepted. According to what we announced in today's press release, 12 patients have been enrolled and 8 can be assessed for response. We've seen 1 complete response that lasted 25 months, 1 nodal complete response that lasted 16 months, and 1 partial response still ongoing at 2 months of follow-up. 5 patients experienced stable disease. 2 of them have received treatment for roughly 12 weeks and remain in the study. 2 more patients receiving treatment haven't yet undergone their disease monitoring assessments. One further patient in the 600-milligram group also achieved a partial response. I want to emphasize that the published overall survival for first relapsed T-cell lymphoma is a median of 5.6 months, while progression-free survival is under 3 months. Clearly, this illness is extremely serious. The median count of prior therapies among our patients is 4. Of great significance are the correlative lab tests on blood and tumors from responding patients, which demonstrated: first, evidence of Th1 skewing; second, a rise in T effector cells in both blood and tumor; and third, greater activation of T cells in the blood and tumor; these results represent the signature of effects on T helper cell differentiation. Put simply, CPI-818 blocks the cells known as Th2, producing what's called Th1 skewing. Th2 cells are frequently the ones implicated in autoimmunity, fibrosis and allergy. Th1 cells are essential for generating cytotoxic T cells, which take part in destroying cancer cells and cells infected by viruses. These results back a novel mechanism of action for eliminating malignant T cells. Our thinking is that we might be triggering a typical antitumor or anti-lymphoma reaction from the host's immune system. Perhaps this same method might be applied to additional tumor types too. Should that prove true, then modulating T cells using 818 might establish a fresh standard for immunotherapy against other cancers, solid tumors among them. To explore that prospect, preclinical work in animal models is currently in progress. Beyond that, our continuing Phase I trial has yielded further observations relevant to allergy. It's established that Th2 cells drive conditions such as asthma, atopic dermatitis, and fibrotic illnesses like idiopathic pulmonary fibrosis, among others. Eosinophilia serves as a major biomarker indicating Th2 overactivity. Elevated eosinophil levels in blood result from cytokines secreted by Th2 cells. Eosinophils, a type of white blood cell, contribute to allergic and autoimmune conditions, and their counts tend to run high in people with T-cell lymphomas. Within our active lymphoma trial, we've observed that 818 lowers circulating eosinophils among multiple patients who had elevated counts before treatment began; these results give us reason to explore 818 for allergic conditions. Encouraging preclinical results with 818 in autoimmunity are also being produced by us. Portions of this were shared earlier at ASH in 2020 and at ASH in 2021; to broaden and strengthen our capacity to push these opportunities forward, we brought on Dr. James Rosenbaum as our new Senior Vice President of Research during late July. Jim holds Board certification in rheumatology and is a leading immunologist whose deep clinical and research expertise centers on inflammation, autoimmunity, arthritic diseases, and how the microbiome influences immunity. He joins us from Oregon Health & Science University, where his roles included Professor of Medicine and Cell Biology and Chair of the Division of Arthritis and Rheumatic Diseases. Jim's first priority will involve developing CPI-818. I'll now hand the call over to him for a short introduction, and he'll also take part in the Q&A segment of this call. Jim?

James Rosenbaum

executive
#4

Thanks, Richard, and good afternoon to all of you. It's a thrill to be with you today, and over the next several months I'm eager to meet many of you, whether online or face-to-face. As Richard mentioned, inflammation and autoimmune disorders have been the focus of my professional life. After I learned about the immunologic properties of CPI-818 and reviewed the early findings in lymphoma patients, I grew genuinely enthusiastic about Corvus. The ITK target has been familiar for quite a while, yet Corvus is the first group to establish that this target might hold valuable therapeutic possibilities across a range of diseases. Even though my tenure at Corvus is still brief, several key reasons make me optimistic about 818 and our broader pipeline. First, CPI-818 is unique. To my knowledge, no other ITK inhibitors are presently in clinical development. One key characteristic of CPI-818 is its exquisite specificity for ITK, which proves crucial for affecting differentiation of T cells. Second, the clinical and preclinical data for CPI-818 are encouraging and speak to its broad potential. We have the chance to help a significant number of patients with T-cell lymphomas, immune-mediated diseases or allergies, and also to deepen understanding of some fundamental immunologic principles. Third, Corvus is a leader in research and development related to the adenosine axis. Our programs, cifo and mupa, have unique properties relative to other programs in development and are Phase II-ready. Taken together, the Corvus portfolio of product candidates creates exciting new opportunities to potentially impact several important areas of medicine; and with that, I will turn it back to Richard.

Richard Miller

executive
#5

I want to thank Jim, and we're eager to move CPI-818 forward along with our other products while he's at the helm. Our belief is that within the coming 6 to 12 months, we're set up to launch clinical trials in autoimmune and/or allergic diseases. Turning next to ciforadenant, which is our antagonist of the adenosine 2A receptor, we're moving ahead with a Phase II study alongside the Kidney Cancer Clinical Trials Consortium in first-line renal cell cancer, centering on the triplet regimen of cifo combined with ipilimumab and nivolumab; this study rests on our 2018 publication that demonstrated synergy between ciforadenant and an anti-CTLA-4 antibody in preclinical tumor models. The study, which is going to enroll as many as 60 patients, should kick off in Q3 of this year. Deep responses will serve as the primary endpoints. By deep responses we mean CRs and PRs featuring more than 50% shrinkage in tumor volume, which mirrors our aim of lifting the plateau on progression-free survival and survival through the addition of ciforadenant. MD Anderson leads the Kidney Cancer Consortium, and it counts several prominent centers among its members, for instance Vanderbilt, Beth Israel of Boston, Cleveland Clinic, UT Southwestern and others. Keep in mind that because this is an open-label, single-arm study, we expect to gain a solid sense of efficacy early on; as for mupadolimab, our B cell-activating anti-CD73, although we are halting the start of our Phase II study, we view it as differentiated within the CD73 space given that it attaches to a unique epitope on the CD73 protein, and on B cells this causes them to activate and differentiate into plasma cells that produce antibodies as well as into memory B cells. Adenosine plays no role in this property. I stress this because we believe the immunomodulatory properties deliver a distinct mechanism of action in immunotherapy. Our collaborator, Angel Pharmaceuticals, is going to keep developing mupadolimab in China, with a Phase I study planned that tests monotherapy as well as combination with pembrolizumab in patients who have advanced lung and head and neck cancer. The CDE in China recently accepted the IND for that study. To wrap up, we think Corvus is nicely positioned, with multiple potential catalysts across our programs over the next 12 months and a lengthened cash runway that now extends into 2024. Among the important near-term milestones is growing enrollment of peripheral T-cell lymphoma patients, together with further Phase I data before this year ends, using CPI-818. Remember that this study will involve Angel Pharmaceuticals, which will handle the China portion. Next, CPI-818 development in autoimmune and allergy continues, aiming to start clinical trials early next year, in early 2023; and third, launching the Phase II ciforadenant study in first-line renal cell cancer together with the Kidney Cancer Consortium during Q3, with the possibility of reading out clinical activity fairly early in enrollment given that the study is open-label. We're eager to share updates on these important initiatives in the quarters ahead. At this point I'll hand the call to the operator for questions and answers. Operator?

Li Watsek

analyst
#6

This is Rosemary calling in on behalf of Li. I've just got a few. So to start with, regarding 818, I'm curious whether you might have any thoughts on the route to approval, plus roughly what the timeline for that would look like.

Richard Miller

executive
#7

Alright. Would you like to share your second question too, or —?

Analyst

analyst
#8

Sure. So my second question is about mupadolimab. Given that upcoming studies in lung cancer will likely be very costly, could you talk about possible BD opportunities?

Richard Miller

executive
#9

Okay. Let's start with how 818 could get approved in lymphoma. Right now, we're running a study of 818 in patients who have relapsed multiple times. The aim of this current ongoing study is to verify the responses we've observed. After that, the following stage would be a Phase II study, once again in patients with advanced recurrent disease. As I said, after one failure, median survival is under 6 months. Therefore, we believe there may be a route to approval as a monotherapy through a single-arm study; and alongside that, I would also — considering the safety profile we've observed with 818 — I would also want to bring it into the frontline setting, likely combined with standard chemotherapy such as CHOP or CHOAP; that approach would require a randomized study. And in such a study, PFS would need to serve as an endpoint. So I envision a single-arm study using monotherapy in advanced disease, with either a subsequent or parallel randomized study in earlier-line peripheral T-cell lymphoma. As you know, this disease lacks good treatments. Some agents are approved, but they aren't very effective. We believe this offers a highly novel mechanism of action that is more active than what some other agents have demonstrated in early development. Now, one more point to add to that — one thing I attempted to highlight in our remarks — is that while treating T-cell lymphoma patients, we are simultaneously examining their normal T cells and B cells along with the rest of their immune function. It's nearly as though we're obtaining several types of information from these T-cell lymphoma studies that we believe can guide us for autoimmune studies. Now, regarding your question on mupadolimab, the lung cancer area has gotten crowded, and lots of people are awaiting further data on TIGIT combinations with anti-PD-1s; we too are waiting to see how that situation resolves. We have a protocol that's ready. We have — it's a protocol I've previously described, which is chemo and pembro with or without mupa; we know which study we need to conduct. We're simply waiting to see how that situation resolves. Since it's a blinded, randomized Phase II study, one reason we chose to pause on it, as I noted, is that we won't be able to review data from it for a certain period, for 12 or 18 months. Meanwhile, putting money into our other programs provides us with data continuously and very rapidly, letting us build value in this fairly difficult environment. Mupa, then, is a one-of-a-kind anti-CD73 agent, and we can't wait to bring it back into the clinic the moment market conditions get better.

Supawat Thongthip

analyst
#10

Supawat from Mara here. My question concerns 818 in autoimmune disease. You previously presented data — preclinical data in GVHD — and I'm wondering whether that indication is the one that fits best given 818's immunologic properties. Or do you believe some other autoimmune diseases would be a better fit? Then my second question: could you discuss how dosing of 818 might differ between TCL and autoimmune diseases?

Richard Miller

executive
#11

All right. Jim — Dr. Rosenbaum, perhaps you can handle the first portion of that question.

James Rosenbaum

executive
#12

Sure. Well, beyond what we've shared regarding acute GVHD, we've also presented findings from the MRL/lpr mouse, a model that shares features with lupus. Findings have been presented by us from a T cell-mediated colitis model, along with results from a psoriasis model in mice. So those represent conditions we're focused on, plus several that Dr. Miller brought up: atopic dermatitis, pulmonary fibrosis and asthma. And I believe we are working through that information to determine which will serve as the first clinical target.

Richard Miller

executive
#13

All right. So let me build on what was just said, and in particular, address what you asked. My first indication wouldn't be graft-versus-host disease, since in our view the conditions Dr. Rosenbaum listed a moment ago — atopic dermatitis, asthma, inflammatory bowel disease, fibrotic diseases — represent enormous opportunities. And in this setting, what we have is an oral product with a novel mechanism of action, one demonstrated to be comparatively safe at doses far above what would be given for autoimmune disease. That leads into your next question, about dosing. For autoimmune diseases, dosing is expected to be reduced, since our real goal involves any autoimmune or allergic condition in which Th2 cells play a part — the ones referred to as Th2 cells, which you're welcome to research. Such conditions are numerous — and each could serve as a target — a possible target — for this treatment. So — though I'd say the 200-milligram dose currently used in peripheral T-cell lymphoma is roughly in the range we'd employ for autoimmune disease. Maybe a bit lower is possible.

Sean Lee

analyst
#14

There are a couple of things I'd like to ask about. To start, regarding 818: given the update coming at ASH, might you give us a brief sense of the type of data we should anticipate — how many patients, which endpoints, what biomarkers? Also, will it come solely from the cohort receiving 200 milligrams, or will there be fresh information on the remaining dose groups too?

Richard Miller

executive
#15

All right. Every dose cohort will get an update from us. In fact, we're examining a few doses higher than 200 as a way to complete our picture of pharmacokinetics and gain a clearer sense of how things look. So at ASH, what we anticipate presenting is data covering, I'd put it at, 40 to 50 patients. That means efficacy findings, safety findings, whatever immunologic findings arise from blood work, plus biopsy findings; and included in that — the abstract is already off to ASH. Naturally, acceptance is still required. And it covers work from Angel in China along with the portion of the study run by Corvus.

Sean Lee

analyst
#16

Okay, and regarding mupa, should we expect further news from the pembrolizumab combination trial? Or has everything been put on hold right now?

Richard Miller

executive
#17

So, we do still have patients being followed from our Phase I trial, and Angel will very soon begin their own Phase I trial in lung cancer and head and neck — those same tumor types we had been targeting. And, thanks for bringing that up. Here at Corvus, we've put this on hold. However, the trial continues with Angel in China, and we will still obtain data from it. The main rationale behind our decision to pause was to concentrate our resources on the remaining 2 programs that we believe can deliver clinical data more quickly and generate some value. So I can't give you a timeline for fresh mupa updates, but we continue to enroll and follow patients alongside Angel. To be clear, we are not enrolling patients at Corvus. What we're doing is following patients who were already in our trial, and Angel will begin enrolling patients soon.

Richard Miller

executive
#18

Appreciate it, operator. Thanks to all of you for being on today's conference call. It's been great to bring everyone up to speed on what's happening at Corvus, and we're eager to share more updates during our quarterly calls. Thanks again, and farewell.

Operator

operator
#19

That brings us to the end of this call. We appreciate everyone joining the presentation today. You're welcome to leave the line now.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Corvus Pharmaceuticals, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Corvus Pharmaceuticals, Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Corvus Pharmaceuticals, Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.